Tofacitinib

Category: pharmacological

Aliases: Xeljanz

Pharmacological Mechanism

JAK1/JAK3 inhibitor — same class effect as baricitinib. Approved for RA, psoriatic arthritis, ulcerative colitis. ORAL Surveillance trial showed worse CV + malignancy signal vs TNFi → boxed warning.

Half-Life (t½)

PO: 3h

Dosing Guidelines

• PO: Typical 10mg (Range: 5 - 22 mg)

Target Organ Systems

• digestive